This study examined whether pro-2-PAM, a
pro-drug dihydropyridine derivative of the
oxime 2-pralidoxime (2-PAM) that can penetrate the brain, could prevent or reverse the central toxic effects of three
nerve agents;
sarin,
cyclosarin, and
VX. The first experiment tested whether pro-2-PAM could reactivate guinea pig
cholinesterase (ChE) in vivo in central and peripheral tissues inhibited by these
nerve agents. Pro-2-PAM produced a dose-dependent reactivation of
sarin- or
VX-inhibited ChE in both peripheral and brain tissues, but with substantially greater reactivation in peripheral tissues compared to brain. Pro-2-PAM produced 9-25% reactivation of
cyclosarin-inhibited ChE in blood, heart, and spinal cord, but no reactivation in brain or muscle tissues. In a second experiment, the ability of pro-2-PAM to block or terminate
nerve agent-induced electroencephalographic seizure activity was evaluated. Pro-2-PAM was able to block
sarin- or
VX-induced
seizures (16-33%) over a dose range of 24-32 mg/kg, but was ineffective against
cyclosarin-induced
seizures. Animals that were protected from
seizures showed significantly less
weight loss and greater behavioral function 24 h after exposure than those animals that were not protected. Additionally, brains were free from neuropathology when pro-2-PAM prevented
seizures. In summary, pro-2-PAM provided modest reactivation of
sarin- and
VX-inhibited ChE in the brain and periphery, which was reflected by a limited ability to block or terminate
seizures elicited by these agents. Pro-2-PAM was able to reactivate blood, heart, and spinal cord ChE inhibited by
cyclosarin, but was not effective against
cyclosarin-induced
seizures.